Poised for robust growth
Alkem Labs is a leading Indian pharmaceutical company engaged in the manufacturing of branded generics, generic drugs, active pharmaceutical ingredients (“APIs”) and Nutraceuticals. Indian business contributes 73% to overall sales while international business contributes for the rest.
View & Valuvation:
We expect revenue and PAT to grow at a CAGR of 18.5 & 21.7% respectively over FY16-19E. Further, EBITDA margin is expected to improve by 280bps on account of increasing launches in chronic products coupled with consolidation in acute therapies. Hence, we initiate Alkem with a BUY rating with a TP of Rs.1926 based on 19x FY19E EPS.
Investments in equity shares, debentures, etc., are not obligations of, or guaranteed by Wealth India Financial Services Pvt. Ltd., and are subject to investment risks. Click here to read our full disclaimer.